UroCCR Database: French Research Network for Kidney Cancer (UroCCR)

November 7, 2022 updated by: University Hospital, Bordeaux

UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)

Within the framework for kidney cancer care, with the recent diversification of treatment modalities of these tumors and the deployment of the concept of multidisciplinary team, it was considered necessary to adapt the research tools to reality of health-care for patients with kidney cancer.

UroCCR is the French research network for kidney cancer, funded by the French National Cancer Institute as part of the call for projects for clinical and biological databases (BCB). Depending on the case presentation and disease evolution, more than a thousand of different variables can be recorded. At the same time, biological samples (plasma, urine, healthy and tumor tissues) are collected.

This database contains a considerable number of information and high added value since it is the result of multiple expertises that make it not only a multidisciplinary tool but also multicenter, allowing fundamental, translational and clinical research.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The UroCCR database is a national medico-scientific network focused on therapeutic management and applied research in kidney cancer.

Secondary objectives:

  1. - Evaluate and compare different surgical approaches in the treatment of kidney cancer,
  2. - Evaluate and compare safety/efficacy of different drugs in the treatment of kidney cancer.

Study Type

Observational

Enrollment (Anticipated)

15000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Angers, France, 49100
        • Recruiting
        • CHU Angers
        • Contact:
          • Pierre Bigot
      • Bordeaux, France, 33076
        • Recruiting
        • CHU Bordeaux
        • Contact:
          • Jean-Christophe BERNHARD
      • Caen, France
        • Recruiting
        • CHU Caen
        • Contact:
          • Arnaud DOERFLER
      • Créteil, France, 94010
        • Recruiting
        • CHU Henri Mondor - APHP
        • Contact:
          • Alexandre Ingels
      • La Tronche, France, 38700
        • Recruiting
        • Chu Grenoble
        • Contact:
          • Jean-Alexandre LONG
      • Lille, France, 59020
        • Recruiting
        • Centre Oscar Lambret
        • Contact:
          • Antoine ADENIS
      • Lille, France, 59037
        • Recruiting
        • CHRU Lille
        • Contact:
          • Arnaud VILLERS
      • Limoges, France, 87042
        • Recruiting
        • CHU Limoges
      • Lyon, France, 69002
        • Recruiting
        • HCL LYON
        • Contact:
          • Philippe PAPAREL
      • Paris, France, 75013
        • Recruiting
        • CHU Kremlin Bicêtre - APHP
        • Contact:
          • Sébastien PARIER
      • Paris, France, 75014
        • Recruiting
        • CH St Joseph
        • Contact:
          • Martin BRENIER
      • Paris, France, 75015
        • Recruiting
        • Hôpital européen Georges Pompidou - APHP
        • Contact:
          • François AUDENET
      • Paris, France
        • Recruiting
        • Hôpital Bichat -APHP
        • Contact:
          • Evangelos Xylinas
      • Paris, France
        • Recruiting
        • Hopital Pitié Salpetriere - APHP
        • Contact:
          • Morgan ROUPRET
      • Paris, France
        • Recruiting
        • Hôpital Tenon - APHP
        • Contact:
          • Olivier TRAXER
      • Poitiers, France
        • Recruiting
        • CHU Poitiers
        • Contact:
          • Thomas CHARLES
      • Reims, France
        • Recruiting
        • CHU Reims
        • Contact:
          • Stéphane LARRE
      • Rennes, France, 35000
        • Recruiting
        • CHU Rennes - Centre Eugène Marquis
        • Contact:
          • Karim BENSALAH
      • Rouen, France, 76031
        • Recruiting
        • CHU Rouen
        • Contact:
          • Christian PFISTER
      • Strasbourg, France, 67000
        • Recruiting
        • CHU Strasbourg
        • Contact:
          • Hervé LANG
      • Toulouse, France, 31059
        • Recruiting
        • CHU Toulouse - Centre Claudius Régaud
        • Contact:
          • Michel SOULIE
      • Tours, France
        • Recruiting
        • CHRU Tours

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with Kidney cancer

Description

Inclusion Criteria:

  • Adult patient with kidney cancer
  • Patient with no opposition to collection of its data for the study

Exclusion Criteria: none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients
Adult patients with kidney cancer
Procedure: Radical nephrectomy versus partial nephrectomy (according surgeon judgement)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Operative time, ,
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Blood loss
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Clinical scores
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dosage of creatininemia to assess the renal function after surgery
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of creatininemia
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of MDRD GFR to assess the renal function after surgery
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of MDRD GFR
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Medical or surgical complication rates with Clavien's grading
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Medical or surgical complication rates with urinary fistula rate
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Medical or surgical complication rates with necessity for nephrectomy or re-exploration
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Safety and efficacy of medical treatment on kidney tumor size evolution
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Imaging data: tumor size evolution
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Safety and efficacy of medical treatment on biological parameters
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Biological parameters
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Progression of the tumor
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Imaging data: tumor location
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Bordeaux

Investigators

  • Principal Investigator: Jean-Christophe BERNHARD, PHU, University Hospital, Bordeaux

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2011

Primary Completion (Anticipated)

December 1, 2024

Study Completion (Anticipated)

December 1, 2024

Study Registration Dates

First Submitted

July 12, 2016

First Submitted That Met QC Criteria

September 20, 2017

First Posted (Actual)

September 26, 2017

Study Record Updates

Last Update Posted (Actual)

November 8, 2022

Last Update Submitted That Met QC Criteria

November 7, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUBX 2011/38

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Cancer

Clinical Trials on Radical nephrectomy versus partial nephrectomy (according surgeon judgement)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe